Zimmer Biomet Surges on Hip Tech | Business and Finance News

Zimmer Biomet’s Q2 earnings crush expectations with $2.18B in revenue, fueled by a booming U.S. hip replacement market and strong adoption of new tech like the Z1 stem and OrthoGrid navigation. Their sales force overhaul is paying off faster than anticipated, while core segments and recent acquisitions show solid momentum. Despite international headwinds, innovation—like iodine-coated hips in Japan—is driving growth. Management raised full-year guidance, signaling confidence, but investors are watching closely for sustained performance, global rollout of robotic shoulders, and continued operational efficiency to protect margins. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/e67321f351f15f43